Penka Kovacheva

Vice President

Contact

  • Los Angeles

Education

Penka Kovacheva coleads Cornerstone Research’s life sciences practice. She specializes in litigation and regulatory investigations within the life sciences and healthcare industries. In addition to being a testifying expert herself, Dr. Kovacheva works closely with academic experts and attorneys, and leads large teams in performing complex economic and statistical analyses on a range of issues within these industries.

In particular, Dr. Kovacheva has extensive experience in:

Antitrust litigation and merger investigations
  • Investigated allegations of anticompetitive delay of generic entry, including alleged reverse payments, product hopping, and noncompete agreements between drug manufacturers
  • Analyzed allegations of price fixing among generic drug manufacturers
  • Examined class certification issues in end-payor and direct purchaser class actions
  • Estimated competitive effects of a vertical merger between a health insurer and a pharmacy benefit manager
Product misrepresentation and product liability matters
  • Assessed the impact of pharmaceutical marketing on prescribers’ behavior and prescription drug sales
  • Analyzed pharmaceutical companies’ drug development decisions
Statistical sampling matters
  • Performed statistical sampling and evaluated sample designs and extrapolation methods to address allegations of Medicare and Medicaid overpayment for healthcare services
  • Assessed the use of sampling to establish liability and damages in False Claims Act matters and government audits of healthcare providers
Intellectual property disputes
  • Analyzed indicators of commercial success and nexus to patent claims in Hatch-Waxman disputes
  • Assessed potential irreparable harm in the context of preliminary injunction motions
Event

American Health Law Association Annual Meeting 2025

Press Release

2025 Antitrust Writing Awards

Podcast/Video

Our Curious Amalgam: How Do We Measure Innovation?

Article

The Impact of Pharmaceutical M&A on Innovation

Article

Most-Favored Entry Clauses in Drug-Patent Litigation Settlements

Case

In re Novartis and Par Antitrust Litigation

Case

In re HIV Antitrust Litigation

Article

The Inflation Reduction Act Could Have Unintended Consequences

  • Women@ Initiative for “Up-And-Coming” Women Competition Professionals, 17 June 2019
  • “Spikes in Drug Prices: Outrageous or Legitimate?,” Health Care and Pharmaceuticals Committee, American Bar Association Section of Antitrust Law, 29 June 2017